Table 2.
Genes involved with acetaminophen metabolism or drug induced liver injury examined for association with maximum ALT elevation over 16 days of daily therapy.
| Gene | CHR | LD Pruning at 0.1, Variant coverage | aSPU P-Value |
|---|---|---|---|
| CYP2E1 | chr10 | 3 | 0.1838 |
| CYP2E1 Promoter | chr10 | 1 | 0.3076 |
| UGT1A | chr2 | 37 | 0.3796 |
| HLA-DRB1 | chr6 | 1 | 0.1318 |
| HLA-DRB5 | chr6 | 1 | 0.8841 |
| FZD5 | chr2 | 3 | 0.0969 |
| SULT1A1 | chr16 | 2 | 0.6893 |
| SULT1E1 | chr4 | 8 | 0.0019* |
| SULT2A1 | chr19 | 4 | 0.1218 |
| CYP2A6 | chr19 | 1 | 0.2997 |
| CYP2D6 | chr22 | 2 | 0.5744 |
| CYP3A4 | chr7 | 6 | 0.2547 |
| UGT2B15 | chr4 | 7 | 0.0949 |
| GSTP1 | chr11 | 2 | 0.6413 |
| CYP1A2 | chr15 | 3 | 0.4655 |
| CD44 | chr11 | 25 | 0.0539 |
| XBP1 | chr22 | 3 | 0.6663 |
| BTNL2 | chr6 | 20 | 0.4775 |
| GRHL3 | chr1 | 12 | 0.8441 |
| ANXA11 | chr10 | 19 | 0.6093 |
*
Following Bonferroni correction with genes with variants included after LD pruning, level of significance was 0.0025. GSTT1, GSTM1, SULT1A4, and SULT1A3 were also tested though after LD pruning, no variants remained and thus, were not included in these analyses.